(NASDAQ: APRE) Aprea Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.82%.
Aprea Therapeutics's earnings in 2026 is -$14,144,831.On average, 6 Wall Street analysts forecast APRE's earnings for 2026 to be -$4,849,111, with the lowest APRE earnings forecast at -$5,562,925, and the highest APRE earnings forecast at -$4,023,187. On average, 6 Wall Street analysts forecast APRE's earnings for 2027 to be -$5,246,463, with the lowest APRE earnings forecast at -$7,370,876, and the highest APRE earnings forecast at -$3,576,166.
In 2028, APRE is forecast to generate -$5,017,986 in earnings, with the lowest earnings forecast at -$5,145,706 and the highest earnings forecast at -$4,619,215.